Health-related quality of life and cognitive functioning in
survivors of oligodendroglioma: An international
cross-sectional investigation

J 2025

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

BOELE, Florien W; Se M FRANCES; Amelie DARLIX; Francois DUCRAY; Stephanie CARTALAT et al.

Základní údaje

Originální název

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

Autoři

Vydání

Neuro-Oncology, Cary, Oxford University Press, 2025, 1522-8517

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00141898

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

cognition; health-related quality of life; low-grade glioma; oligodendroglioma; survivorship

Štítky

14110812, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 4. 2026 10:12, Mgr. Tereza Miškechová

Anotace

V originále

Background: Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed >= 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumour location; treatments delivered; time since treatment; current medication;) were explored with regression analyses. Results: In total, 237 patients M=9.9 years post-diagnosis (sd=4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (post-hoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning. Trial registration: NCT04708548.

Citovat

BOELE, Florien W; Se M FRANCES; Amelie DARLIX; Francois DUCRAY; Stephanie CARTALAT; Estelle GUERDOUX; Emeline TABOURET; Michael C BURGER; Isabelle RYDEN; Annika MALMSTROM; Elodie VAULEON; Tomáš KAZDA; Mirjam RENOVANZ; Jan-Michael WERNER; Liam WELSH; Paul SANGHERA; Caroline DEHAIS; Isacco DESIDERI; Catherine MCBAIN; Shaveta MEHTA; Hannah LORD; Rajesh JENA; Karen FOWERAKER; Keyoumars ASHKAN; Julien ENGELHARDT; Veronique BOURG; Ulrich HERRLINGER; Lawson McLean AARON; Caroline HERTLER; Lene HALDBO-CLASSEN; Rikke H DAHLROT; Georges NOEL; Xavier DURANDO; Ioana HRAB; Evangelia RAZIS; Michael WELLER; Aida MUHIC a Martin KLEIN. Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation. Neuro-Oncology. Cary: Oxford University Press, 2025, roč. 27, č. 11, s. 2959-2974. ISSN 1522-8517. Dostupné z: https://doi.org/10.1093/neuonc/noaf172.

@article{2515038,
   author = {Boele, Florien W and Frances, Se M and Darlix, Amelie and Ducray, Francois and Cartalat, Stephanie and Guerdoux, Estelle and Tabouret, Emeline and Burger, Michael C and Ryden, Isabelle and Malmstrom, Annika and Vauleon, Elodie and Kazda, Tomáš and Renovanz, Mirjam and Werner, JanandMichael and Welsh, Liam and Sanghera, Paul and Dehais, Caroline and Desideri, Isacco and McBain, Catherine and Mehta, Shaveta and Lord, Hannah and Jena, Rajesh and Foweraker, Karen and Ashkan, Keyoumars and Engelhardt, Julien and Bourg, Veronique and Herrlinger, Ulrich and Aaron, Lawson McLean and Hertler, Caroline and HaldboandClassen, Lene and Dahlrot, Rikke H and Noel, Georges and Durando, Xavier and Hrab, Ioana and Razis, Evangelia and Weller, Michael and Muhic, Aida and Klein, Martin},
   article_location = {Cary},
   article_number = {11},
   doi = {https://doi.org/10.1093/neuonc/noaf172},
   keywords = {cognition; health-related quality of life; low-grade glioma; oligodendroglioma; survivorship},
   language = {eng},
   issn = {1522-8517},
   journal = {Neuro-Oncology},
   title = {Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation},
   url = {https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf172/8210167?login=true},
   volume = {27},
   year = {2025}
}

TY  - JOUR
ID  - 2515038
AU  - Boele, Florien W - Frances, Se M - Darlix, Amelie - Ducray, Francois - Cartalat, Stephanie - Guerdoux, Estelle - Tabouret, Emeline - Burger, Michael C - Ryden, Isabelle - Malmstrom, Annika - Vauleon, Elodie - Kazda, Tomáš - Renovanz, Mirjam - Werner, Jan-Michael - Welsh, Liam - Sanghera, Paul - Dehais, Caroline - Desideri, Isacco - McBain, Catherine - Mehta, Shaveta - Lord, Hannah - Jena, Rajesh - Foweraker, Karen - Ashkan, Keyoumars - Engelhardt, Julien - Bourg, Veronique - Herrlinger, Ulrich - Aaron, Lawson McLean - Hertler, Caroline - Haldbo-Classen, Lene - Dahlrot, Rikke H - Noel, Georges - Durando, Xavier - Hrab, Ioana - Razis, Evangelia - Weller, Michael - Muhic, Aida - Klein, Martin
PY  - 2025
TI  - Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation
JF  - Neuro-Oncology
VL  - 27
IS  - 11
SP  - 2959-2974
EP  - 2959-2974
PB  - Oxford University Press
SN  - 15228517
KW  - cognition
KW  - health-related quality of life
KW  - low-grade glioma
KW  - oligodendroglioma
KW  - survivorship
UR  - https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf172/8210167?login=true
N2  - Background: Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed >= 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumour location; treatments delivered; time since treatment; current medication;) were explored with regression analyses. Results: In total, 237 patients M=9.9 years post-diagnosis (sd=4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (post-hoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning. Trial registration: NCT04708548.
ER  -

BOELE, Florien W; Se M FRANCES; Amelie DARLIX; Francois DUCRAY; Stephanie CARTALAT; Estelle GUERDOUX; Emeline TABOURET; Michael C BURGER; Isabelle RYDEN; Annika MALMSTROM; Elodie VAULEON; Tomáš KAZDA; Mirjam RENOVANZ; Jan-Michael WERNER; Liam WELSH; Paul SANGHERA; Caroline DEHAIS; Isacco DESIDERI; Catherine MCBAIN; Shaveta MEHTA; Hannah LORD; Rajesh JENA; Karen FOWERAKER; Keyoumars ASHKAN; Julien ENGELHARDT; Veronique BOURG; Ulrich HERRLINGER; Lawson McLean AARON; Caroline HERTLER; Lene HALDBO-CLASSEN; Rikke H DAHLROT; Georges NOEL; Xavier DURANDO; Ioana HRAB; Evangelia RAZIS; Michael WELLER; Aida MUHIC a Martin KLEIN. Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation. \textit{Neuro-Oncology}. Cary: Oxford University Press, 2025, roč.~27, č.~11, s.~2959-2974. ISSN~1522-8517. Dostupné z: https://doi.org/10.1093/neuonc/noaf172.

Přehled o publikaci